Pentobarbital will decrease the level or influence of lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with potent CYP3A4 inducers can lead to diminished serum concentrations and lack of antimalarial efficacy pentobarbital will decrease the extent or outcome of budesonide by impacting hepatic/intestinal enzyme CYP3A4 metabolism... https://ghomsheig666fti2.bloggerchest.com/profile